The review, conducted according to the rigorous PRISMA 2020 guidelines for systematic literature synthesis, was led by Muhammad Mazhar Fareed of the University of Verona and Sergey Shityakov of ITMO University and Sechenov University. Its central finding is a growing convergence between artificial intelligence and precision therapeutics, a trend visible across target identification, drug repurposing, virtual screening, and clinical trial prediction. Yet the authors caution that real-world deployment demands far more than clever algorithms: robust experimental validation, interdisciplinary collaboration, explainable AI, and globally harmonized regulatory standards are all prerequisites for AI systems to earn their place in clinical practice.

The technical core of the review lies in its treatment of machine learning as the engine of modern drug discovery. Traditional pharmaceutical pipelines are notoriously expensive and inefficient, with most candidate molecules failing before reaching the market. Machine learning attacks this attrition problem at multiple stages. Supervised and unsupervised algorithms can mine vast chemical and biological datasets to identify promising disease targets, while virtual screening models such as QSAR and deep QSAR frameworks predict how candidate molecules will behave before a single experiment is run. The review highlights how fingerprinting techniques that encode protein-ligand interactions and graph neural networks that respect molecular symmetry have dramatically improved the accuracy of interatomic potential modeling and binding affinity prediction.

Deep learning architectures receive particularly detailed attention. Convolutional and recurrent networks, transformers, and equivariant graph neural networks now power tasks ranging from predicting protein-ligand binding to modeling cardiotoxicity risks in patients receiving chemotherapeutic agents such as anthracyclines. Generative models represent perhaps the most visually striking advance: variational autoencoders, generative adversarial networks, normalizing flows, and autoregressive chemical language models can design entirely novel molecules with desired properties. The review cites bidirectional molecule generation with recurrent neural networks and conditional generative pre-trained transformers as examples of de novo design systems that effectively treat chemistry as a language, learning molecular grammar from known compounds and then writing new drug candidates in that language.

Large language models occupy their own chapter in this transformation. Originally trained on text, these systems have been adapted to translate between molecular structures and natural language, answer complex chemistry questions, mine patents for chemical function insights, and even propose protein structures. The review notes that multimodal large language models can now integrate textual, structural, and biological data, while reinforcement learning feedback loops refine model outputs toward synthetically feasible and biologically active molecules. These capabilities extend beyond discovery into clinical development, where language models support literature mining, trial design, and pharmacovigilance.

The most forward-looking portion of the review concerns quantum computing. Quantum computers manipulate information using qubits, which exploit superposition and entanglement to represent molecular systems in ways classical bits cannot. Because molecules are inherently quantum objects, simulating their electronic structure on classical hardware scales exponentially with system size, whereas quantum algorithms promise polynomial scaling for certain problems. The review draws on foundational work in quantum machine learning and quantum computational chemistry to argue that quantum-enhanced simulations could eventually calculate electronic properties, reaction pathways, and binding energies with accuracy unattainable by classical methods. Hybrid quantum-classical approaches, combining quantum mechanical and molecular mechanical treatments of pharmaceutical systems, already point toward this future, and platforms that merge AI with quantum mechanics now offer explainable drug discovery pipelines.

Personalized medicine emerges as the clinical face of this computational revolution. The review describes how integrating multi-omics data, spanning genomics, transcriptomics, proteomics, and metabolomics, enables data-driven therapeutic decisions tailored to individual patients. Pharmacogenomic interaction landscapes, patient-derived cell models, and AI-based 3D-QSAR models of repurposed drugs illustrate how computational predictions can be anchored in biological reality. Digital twins, virtual replicas of patients or physiological systems, extend this personalization by allowing clinicians to simulate disease progression and treatment responses in silico. Wearable devices add another dimension, feeding continuous real-world physiological data into machine learning models that can detect conditions such as Parkinson’s disease years before clinical diagnosis or predict dangerous blood pressure fluctuations in real time.

Despite this impressive toolkit, the review is notably candid about the field’s limitations. Data quality remains a fundamental weakness: biased, sparse, or inconsistently curated datasets propagate errors into model predictions, and models trained on historical data often fail prospectively. Interpretability is another critical concern, as clinicians and regulators understandably resist black-box recommendations they cannot explain. Ethical challenges loom equally large, including patient privacy in the electronic medical record era, algorithmic bias across populations, and the need for legal frameworks governing AI in medicine. The regulatory landscape is still maturing, with agencies worldwide grappling with how to validate, monitor, and approve drugs whose discovery pathways involve adaptive, opaque computational systems.

The authors conclude that the future of AI-enabled pharmaceutical innovation lies in convergence rather than replacement. Classical machine learning, generative modeling, and quantum computation each possess distinct comparative strengths, and no single approach will dominate every stage of the discovery and development pipeline. Realizing the vision of faster, cheaper, and more personalized medicines will require sustained cross-sector collaboration between academia, industry, and regulators, alongside investment in explainable AI and international data standards. What emerges from the review is neither hype nor dismissal but a structured map of where the field stands, where it is falling short, and which directions offer the greatest scientific and clinical payoff as artificial intelligence matures from promising tool into essential infrastructure for modern medicine.

Subject of Research: AI-driven drug discovery and personalized medicine integrating quantum computing and next-generation technologies

Article Title: AI-driven drug discovery and personalized medicine: integrating quantum computing and next-generation technologies

Article References: Fareed, M. M., & Shityakov, S. (2026). AI-driven drug discovery and personalized medicine: integrating quantum computing and next-generation technologies. Quantum Machine Intelligence, 8(2), Article 94. https://doi.org/10.1007/s42484-026-00435-z

Image Credits: AI Generated

DOI: 10.1007/s42484-026-00435-z

Keywords: artificial intelligence, machine learning, deep learning, drug discovery, precision medicine, quantum computing, multiomics integration, digital twins, large language models, pharmacovigilance, regulatory challenges, PRISMA

The framework, developed by Seowon Chang, Alexander Fleischmann and Ying Ma, addresses a problem that has grown acute as spatial assays have diversified. Transcriptome-plus-protein platforms such as SPOTS and spatial CITE-seq, epigenome-transcriptome methods that jointly capture chromatin accessibility or histone marks alongside RNA, metabolomic imaging and multiplexed approaches such as spatial-Mux-seq each carry modality-specific signals that generic integration tools tend to wash out. Earlier software could typically merge only two modalities, struggled with the massive spot counts of Visium HD, and returned a single consensus answer with no indication of where the model was guessing. SCIGMA’s designers set out to build a system that was scalable, generalizable across platforms and honest about its own uncertainty.

Architecturally, SCIGMA combines two ideas that have proven powerful in machine learning but had not been married in quite this way for spatial biology. The first is a multiview graph neural network built on graph attention layers, which represents each spatial location as a node connected to its tissue neighbors, letting the model learn from both molecular measurements and the physical arrangement of the tissue. Each modality is encoded through its own branch, so transcriptomic, proteomic, epigenomic and metabolic information is transformed into a shared latent space without being forced into a single flattened feature matrix. The second idea is an uncertainty-aware contrastive learning objective: by treating temperature as a learnable, uncertainty-linked quantity, the model learns to pull together representations of the same location seen through different molecular lenses while pushing apart mismatched views, and it modulates how strongly it aligns views depending on how reliable the data at that location appear to be.

This uncertainty machinery is more than a statistical nicety. After training, SCIGMA produces spatially resolved uncertainty maps that highlight regions of biological or technical heterogeneity — tumor margins, regions with mixed cell populations, or spots where assay quality degrades. The authors show that uncertainty estimates flag locations where feature reconstruction error is highest, meaning researchers can see precisely where the integrated representation is least trustworthy rather than accepting a smoothed-over consensus. Interpretability was a design goal throughout: the framework preserves modality-specific signals within its joint embedding, so users can trace which molecular layer drives a given spatial domain and recover regulatory programs that are visible only in, say, the chromatin channel and not the transcriptome.

The evaluation was unusually broad. The team benchmarked SCIGMA across 19 datasets spanning eight modalities, ten tissue types and nine technological platforms, ranging from spatial epigenome-transcriptome profiling of the postnatal mouse brain to protein-plus-RNA measurements of the mouse spleen, single-cell-resolution Xenium Prime datasets from human ovarian and cervical cancers, and enormous Visium HD sections of mouse intestine and human colorectal cancer with more than one million spots each. Where ground truth allowed comparison, SCIGMA outperformed existing methods on spatial domain detection, preservation of modality-specific information, feature reconstruction and reproducibility across repeated runs — a metric that matters given growing concern about the fragility of machine learning models in biomedical data science.

The biological case studies illustrate what multimodal integration buys that single-modality analysis cannot. In the mouse brain, combining chromatin accessibility or histone modification data with transcriptomics let SCIGMA refine cortical layers and white matter boundaries beyond what RNA alone revealed, and to link transcriptional identities with the regulatory elements that govern them. In the spleen, joint transcriptome-proteome analysis sharpened the demarcation of follicles, marginal zones and T cell zones, tying protein-level markers such as CD19 and CD3 components to their local transcriptional contexts. Analyses of Xenium Prime tumor sections demonstrated that the framework resolves intratumoral heterogeneity, distinguishing tumor epithelial niches, stromal compartments and immune infiltrates while its uncertainty layer highlights the unstable boundary regions where tumor biology is most contested.

Scalability was addressed head-on. Naive graph neural networks choke when every spot in a Visium HD section becomes a node in a graph with millions of vertices. SCIGMA incorporates efficient sampling strategies and nearest-neighbor retrieval, borrowing ideas from the Faiss library, to keep training tractable, and the authors demonstrate full-length analysis of Visium HD datasets exceeding one million spatial locations. Equally important is extensibility: the framework is modular, so when a future technology profiles six, seven or more molecular layers simultaneously, additional modality encoders can be attached without redesigning the core model. The team demonstrated this flexibility on spatial-Mux-seq mouse brain data, simultaneously integrating five modalities into a coherent joint representation.

Software accessibility rounded out the release. The SCIGMA package, along with scripts reproducing every published analysis and a suite of tutorials, is openly available through GitHub and archived on Zenodo, supporting the reproducibility standards the paper explicitly engages with. Funding came from the National Science Foundation and the National Institutes of Health, and the work was carried out at Brown’s Center for Computational Molecular Biology with computational support from the university’s Center for Computation and Visualization. The authors report no competing interests, and the article underwent peer review by researchers including Mengjie Chen, Zhaoheng Li and Wei Sun.

For the field, SCIGMA arrives at a moment when the volume and variety of spatial data are outpacing analysis tools. High-resolution platforms such as Visium HD and Xenium Prime are making million-spot, subcellular-resolution datasets routine, and multiplexed assays are stacking molecular layers that earlier software simply could not combine. A framework that handles five modalities, scales to the largest current datasets, runs across platforms without platform-specific tuning, and quantifies its own confidence offers a kind of common analytical ground that spatial biology has lacked. If it holds up in broad community use, the practical effect will be that researchers spend less time wrestling incompatible data formats into fragile pipelines and more time asking biological questions — about how tumors orchestrate their microenvironments, how cortical architecture is patterned, and how genomic regulation plays out across the geography of living tissue.

Subject of Research: Development of SCIGMA, a scalable uncertainty-aware deep learning framework for integrating spatial multiomics data across modalities and platforms

Article Title: Scalable, generalizable and uncertainty-aware integration of spatial multiomics across diverse modalities and platforms with SCIGMA

Article References: Scalable, generalizable and uncertainty-aware integration of spatial multiomics across diverse modalities and platforms with SCIGMA. (n.d.). https://doi.org/10.1038/s41588-026-02706-8

Image Credits: AI Generated

DOI: 10.1038/s41588-026-02706-8

Keywords: spatial omics, multiomics integration, deep learning, graph neural networks, contrastive learning, uncertainty estimation, spatial transcriptomics, tumor heterogeneity, spatial domain detection, Visium HD, Xenium Prime, computational biology